Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Research & Development (2016 - 2025)

Historic Research & Development for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $2.1 million.

  • Harvard Bioscience's Research & Development fell 1694.59% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 2011.04%. This contributed to the annual value of $10.4 million for FY2024, which is 1154.37% down from last year.
  • Harvard Bioscience's Research & Development amounted to $2.1 million in Q3 2025, which was down 1694.59% from $2.2 million recorded in Q2 2025.
  • Harvard Bioscience's Research & Development's 5-year high stood at $3.5 million during Q2 2022, with a 5-year trough of $2.1 million in Q3 2025.
  • Over the past 5 years, Harvard Bioscience's median Research & Development value was $2.8 million (recorded in 2023), while the average stood at $2.7 million.
  • As far as peak fluctuations go, Harvard Bioscience's Research & Development surged by 4238.27% in 2021, and later plummeted by 2609.52% in 2024.
  • Quarter analysis of 5 years shows Harvard Bioscience's Research & Development stood at $3.0 million in 2021, then decreased by 3.46% to $2.8 million in 2022, then grew by 10.57% to $3.2 million in 2023, then fell by 26.1% to $2.3 million in 2024, then dropped by 8.42% to $2.1 million in 2025.
  • Its Research & Development stands at $2.1 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.3 million for Q1 2025.